Droxidopa in Treating Patients With Neurogenic Hypotension
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004478|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : September 18, 2008
Please note that the continuation study can be found at http://clinicaltrials.gov/show/NCT00633880.
RATIONALE: Neurogenic hypotension is a fall in blood pressure that occurs when one moves from a lying down to a standing position or after eating a meal. It causes one to feel dizzy, light headed, and weak. Neurogenic hypotension is caused by a problem in the part of the nervous system that controls such functions as heart rate and blood pressure. Droxidopa, a drug that may increase blood pressure, may be an effective treatment for neurogenic hypotension.
PURPOSE: Clinical trial to study the effectiveness of droxidopa in treating patients who have neurogenic hypotension.
|Condition or disease||Intervention/treatment|
|Shy-Drager Syndrome Orthostatic Hypotension||Drug: droxidopa|
Patients receive escalating doses of droxidopa or placebo for 7-14 days. Patients undergo blood pressure measurements hourly in both supine and standing positions.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Study of Droxidopa in Patients With Neurologic Hypotension|
|Study Start Date :||March 1999|
|Primary Completion Date :||March 2006|
|Study Completion Date :||March 2006|
U.S. FDA Resources
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004478
|United States, New York|
|New York University School of Medicine|
|New York, New York, United States, 10016|
|Study Chair:||Horacio Kaufmann, MD||New York University School of Medicine|